"As the authors emphasize, their study gives the therapist an evidence-based perspective on the use of allogeneic stem-cell transplantation in the patient with acute myelogenous leukemia who has entered a chemotherapy-induced remission, always recognizing that these group data may require modification to satisfy the special circumstances of an individual patient," he said.
Dr. Barton A Kamen, chief medical officer at the Leukemia & Lymphoma Society, thinks this study will help doctors develop treatment plans.
"If I find out I have acute myeloid leukemia, I want them to do my cytogenetics and tailor the therapy to fit me and my disease," Kamen said. "This article confirms that."
For more information on acute myeloid leukemia, visit the American Cancer Society.
SOURCES: John Koreth, M.B.B.S., Ph.D., Dana Farber Cancer Institute, Boston; Marshall A. Lichtman, M.D., professor, medicine, biochemistry and biophysics, University of Rochester Medical Center, New York; Barton A. Kamen, M.D., Ph.D., chief medical officer, Leukemia & Lymphoma Society, White Plains, N.Y.; June 10, 2009, Journal of the American Medical Association
All rights reserved